Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Immunitybio Inc

Current price
5.96 USD +0.09 USD (+1.53%)
Last closed 5.87 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 4 213 516 544 USD
Yield for 12 month +117.52 %
21.11.2021 - 28.11.2021

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

7.5 USD

P/E ratio

Dividend Yield

Current Year

+622 000 USD

Last Year

+240 000 USD

Current Quarter

+40 000 USD

Last Quarter

+139 000 USD

Current Year

-17 890 000 USD

Last Year

-23 952 000 USD

Current Quarter

-4 515 000 USD

Last Quarter

-4 425 000 USD

Key Figures IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -326 592 992 USD
Operating Margin TTM -237990 %
PE Ratio
Return On Assets TTM -57.95 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 7.5 USD
Revenue TTM 302 000 USD
Book Value -1.02 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -88.9 %
Dividend Yield
Gross Profit TTM 240 000 USD
Earnings per share -1.03 USD
Diluted Eps TTM -1.03 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics IBRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation IBRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 6301.8464
Price Sales TTM 5561.8735
Enterprise Value EBITDA -8.9865
Price Book MRQ

Financials IBRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators IBRX

For 52 weeks

1.25 USD 10.53 USD
50 Day MA 6.65 USD
Shares Short Prior Month 53 425 524
200 Day MA 4.26 USD
Short Ratio 4.34
Shares Short 53 472 406
Short Percent 34.16 %

Dynamics of changes in the value of assets




212.49 USD Apple Inc -1.32 (-0.62%)
Detailed analytics

ETF funds



13.36 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.53 (-3.54%)
Detailed analytics



2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics